Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting the ALZEVIT study, a large, nationwide, digital observational research project in France focused on Alzheimers disease prevention and early identification. It aims to create a comprehensive registry of Apolipoprotein E APOE genotypes, especially identifying individuals at high genetic risk such as APOE b54 carriers and b54b54 homozygotes. This work supports precision prevention strategies amid emerging treatments most effective in early or preclinical Alzheimers stages and is sponsored by Firalis SA with collaboration from French memory centers. Participants aged 45 and older enroll online, provide electronic consent, and self-collect saliva samples at home using kits for centralized APOE genotyping. The study has two phases Phase A 0-18 months will enroll 50,000 participants to determine national APOE genotype frequencies, create a secure registry, and conduct remote cognitive and risk factor assessments. Phase B 12-24 months includes detailed evaluations of about 2,350 selected participants with clinical exams, MRI scans, cognitive testing, and multi-omics biomarker profiling, performed at memory centers or via telemedicine. Participants provide information on demographics, health history, lifestyle, and complete cognitive questionnaires with periodic online follow-ups. The study measures APOE genotype distribution, the feasibility of large-scale genetic screening, and identifies high-risk individuals while securely tracking data over time. Phase B adds detailed clinical, biomarker, and environmental analyses to better understand Alzheimers progression and risk factors. The study aims to build a national infrastructure to support prevention research, facilitate trial recruitment, and advance personalized approaches to Alzheimers disease.
Actively Recruiting
Healthy Volunteer
This research aims to validate the stability of various diagnostic biomarkers measured by Firalis IVD tests in healthy volunteers. The study focuses on biomarkers such as long non-coding RNAs lncRNAs, small non-coding RNAs sncRNAs, messenger RNAs mRNAs, proteins, lipids, and metabolites, also examining the effects of gender, age, and nutrition on these markers. Firalis SA and its affiliate Amoneta Diagnostics SAS are developing these tests for major diseases including cardiovascular and neurodegenerative disorders, supporting the analytical validation phase of their diagnostic tools. Participants in this study will undergo biomarker-based in-vitro diagnostic IVD tests developed by Firalis. The tests involve collecting biological samples to analyze the expression levels of these biomarkers under different conditions, such as before and after breakfast intake. This study includes a single group of healthy volunteers, and the focus is on stability and expression level assessments rather than treatment or intervention. The study does not involve medication or placebo but collects data to support diagnostic test validation. During the study, participants will provide biological samples at baseline fasting, before breakfast and then again one hour after breakfast to measure biomarker expression. Researchers will analyze the expression of lncRNAs, sncRNAs, mRNAs, and soluble proteins at these timepoints. The study also considers factors like age, gender, nutrition, and time intervals between sample collections. Participant involvement includes signing informed consent, complying with study procedures, and attending scheduled sample collection visits. The study duration extends until April 2027, with the primary outcome measured by biomarker expression changes before and after breakfast.